A non-invasive, outpatient therapy which allows patients to return to routine immediately after treatment

1. INSIGHTEC for
STARTUP
NATION
Maurice R. Ferré, MD
May 17th, 2016

2. THE VISION BEHIND THE STARTUP: HISTORY OF SURGERY
10,000 years ago Craniotomies
performed surgery and
patients survived
1980’s - Introduction of
minimally invasive procedures
2000’s - Introduction of non-
invasive procedures

3. THE VISION BEHIND THE STARTUP
• Surgery is an old discipline -> proof of
Craniotomies that were done ~10,000 years
ago and the patient survived
• If surgery survived for such a long time in a
fast-paced environment, it must have positive
attributes

4. INVASIVE SURGERY DRAWBACKS
• Trauma
• Morbidity
• Slow recovery
• Collateral damage (on the way to the target)
• 5% to 10% adverse events on average
• Infection
• Reactions to the anesthesia
• Excessive bleeding
-SURGERY DISADVANTAGES
-
-• Focal therapy (vs. systemic therapy)
• Real time feedback on treatment outcome (by
surgeon’s vision and palpation)
• Ability to fix functionality
SURGERY BENEFITS
+

5. A non-invasive,
outpatient therapy which
allows patients to return
to routine immediately
after treatment
.
THE VISION BEHIND THE STARTUP

6. TRANSLATING THE IDEA INTO A REALITY
WE NEEDED TO
• See inside the body
• Destroy tumors deep inside the body without
collateral damage
• Provide real time feedback on tissue viability
• Monitor treatment outcomes in real time
• Develop treatment strategies for a safer
treatment (<1% adverse events)
• Demonstrate minimal trauma, morbidity and
fast recovery

7. www.insightec.com
INSIGHTEC’S TECHNOLOGY
Non-invasive therapy platform that
combines two proven technologies -
High intensity focused ultrasound and
Magnetic Resonance Imaging.
The high intensity focused ultrasound
(FUS) generates heat at the focal point
to ablate the target tissue.
The MRI enables:
1. Identification and targeting
2. Monitoring the treatment
progress in real time, using
thermometry information

8. INSIGHTEC IN A SNAP SHOT - VIDEO

9. COMPANY PROFILE
• Developed Exablate® - the first
FDA approved therapeutic device
using MR-guided Focused
Ultrasound
• INSIGHTEC is a privately held
Israeli company founded in 1999
• 172 employees worldwide
• First to develop technology to
successfully steer and focus
ultrasound through the cranium
• $300K in investments to date
Headquartered
in Haifa, Israel.
Regional offices
in US, China,
Japan and
Europe
OVER 14,000
EXABLATE
TREATMENTS
PERFORMED

10. Voted one of the top 10 innovative
companies to watch for 2016
INSIGHTEC AWARDS
Time magazine voted INSIGHTEC’S
technology as one of the best 50 technologies
in 2011.
INSIGHTEC was included in the World
Medical Innovation Forum’s “Disruptive
Dozen” list
The World Economic Forum has
selected INSIGHTEC as one of its
Technology Pioneers for 2008

11. REGULATORY
STATUS
NEUROSURGERY ONCOLOGY
WOMEN'S
HEALTH
• Essential tremor
• Tremor dominant
Parkinson’s
Disease
• Neuropathic pain
• Pain palliation of
bone metastasis
• Primary bone
tumors
• Bone metastasis
• Uterine fibroids (Family
Complete, now removed)
• Uterine fibroids &
Adenomyosis (Future
fertility)
• Commercially approved in
Japan, Australia, China,
Korea and Russia

12. OUR GLOBAL
FOOTPRINT
An install base of ~120 sites around
the globe, our customers include
well-renowned centers of excellence
Americas
17 USA
2 Canada
1 Mexico
2 Brazil
Europe
4 Germany
11 Italy
3 UK
2 Switzerland
2 Spain
1 Poland
3 France
1 Czech
Republic
Asia
9 Japan
4 Korea
8 China
2 Singapore
1 Taiwan
1 Malaysia
2 Australia
4 India
1 Vietnam
2 GE
6 Russia
1
Kazakhstan
2 Israel
1 HK

13. STATE OF RESEARCH & REGULATORY APPROVAL
-

14. THANK YOU!